Myriad Genetics, Inc [NASDAQ: MYGN] loss -5.62% on the last trading session, reaching $4.03 price per share at the time.
If compared to the average trading volume of 1.58M shares, MYGN reached a trading volume of 7282737 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Myriad Genetics, Inc [MYGN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MYGN shares is $9.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MYGN stock is a recommendation set at 2.88. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wolfe Research have made an estimate for Myriad Genetics, Inc shares, keeping their opinion on the stock as Peer Perform, with their previous recommendation back on May 08, 2025. The new note on the price target was released on May 07, 2025, representing the official price target for Myriad Genetics, Inc stock. On March 12, 2025, analysts increased their price target for MYGN shares from 11.50 to 12.50.
The Average True Range (ATR) for Myriad Genetics, Inc is set at 0.65, with the Price to Sales ratio for MYGN stock in the period of the last 12 months amounting to 0.45. The Price to Book ratio for the last quarter was 0.53, with the Price to Cash per share for the same quarter was set at 1.00.
Trading performance analysis for MYGN stock
Myriad Genetics, Inc [MYGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -43.48. With this latest performance, MYGN shares dropped by -47.87% in over the last four-week period, additionally sinking by -77.40% over the last 6 months – not to mention a drop of -79.82% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MYGN stock in for the last two-week period is set at 17.69, with the RSI for the last a single of trading hit 14.38, and the three-weeks RSI is set at 20.68 for Myriad Genetics, Inc [MYGN]. The present Moving Average for the last 50 days of trading for this stock 8.65, while it was recorded at 6.17 for the last single week of trading, and 17.25 for the last 200 days.
Myriad Genetics, Inc [MYGN]: A deeper dive into fundamental analysis
Myriad Genetics, Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.71 and a Current Ratio set at 1.90.
Myriad Genetics, Inc [MYGN]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MYGN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Myriad Genetics, Inc go to 25.05%.
An analysis of Institutional ownership at Myriad Genetics, Inc [MYGN]
The top three institutional holders of MYGN stocks are: BLACKROCK INC. with ownership of 15.15 million shares, which is approximately 16.7227%. VANGUARD GROUP INC, holding 10.06 million shares of the stock with an approximate value of $$246.18 million in MYGN stocks shares; and VANGUARD GROUP INC, currently with $$202.1 million in MYGN stock with ownership which is approximately 9.1197%.
